{"product_id":"nichiiko-business-model-canvas","title":"Nichi-Iko Pharmaceutical Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Business Model Canvas: Nichi-Iko Pharmaceutical—Download, Benchmark, Execute\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Nichi-Iko Pharmaceutical’s strategic playbook with our concise Business Model Canvas—detailing value propositions, key partners, revenue streams, and cost structure to reveal how the company scales and sustains competitive advantage; perfect for investors, consultants, and founders seeking actionable, ready-to-use insights—download the full Word\/Excel canvas to benchmark, plan, and execute with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Investment Partners and J-STAR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing prior revitalization, the partnership with J-STAR and affiliated funds remains a financial cornerstone for Nichi-Iko Pharmaceutical as of late 2025, providing over ¥8.5 billion in equity and mezzanine injections since 2022 and a 12% minority stake that stabilizes capital structure.\u003c\/p\u003e\n\u003cp\u003eThese partners supply capital and board-level oversight to sustain modern production upgrades (¥2.1 billion invested in 2024–25) and allow management to prioritize multi-year growth rather than short-term liquidity fixes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Biosimilar Development Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNichi-Iko partners with international biotech firms to co-develop and license biosimilars for Japan, sharing R\u0026amp;D costs and technical risk; these alliances cut development spend—often ¥5–15 billion per program—and speed time-to-market by 12–24 months. By end-2025, such deals underpin Nichi-Iko’s push in biologics, supporting projected biosimilar revenue growth of ~25% CAGR in its biologics segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Wholesaler Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNichi-Iko maintains long-term ties with Japan’s major wholesalers (including Toho Pharmaceutical and Alfresa Group partners), using their logistics to supply ~20,000 hospitals and pharmacies nationwide and cover all 47 prefectures; in 2024 these channels helped stabilize domestic shipments that made up ~70% of Nichi-Iko’s ¥112.3 billion revenue. These partnerships are key for inventory control and meeting Japan’s essential-medicine supply mandates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTo cut costs and handle demand swings, Nichi-Iko uses domestic and international contract manufacturing organizations (CMOs), letting it scale generic lines without major capex; in 2024 CMOs handled about 35% of production volume, saving an estimated ¥2.4 billion in capex-equivalent costs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% of volume via CMOs (2024)\u003c\/li\u003e\n\u003cli\u003e¥2.4 billion capex avoided (est., 2024)\u003c\/li\u003e\n\u003cli\u003eFast scale-up for NHI price-list shifts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpcollaborations with universities and specialized medical centers advance nichi-iko pharmaceutical r clinical trial execution supplying expert input access to patient cohorts for bioequivalence safety studies by late these ties prioritize less-saturated specialty areas raising average success value per program versus\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eAccess to patient pools for BE\/safety trials\u003c\/li\u003e\u003cli\u003eExpert clinical input raises study quality ~15%\u003c\/li\u003e\u003cli\u003eFocus shift to specialty areas by late 2025\u003c\/li\u003e\u003cli\u003eReduces generic-price competition risk\u003c\/li\u003e\n\u003c\/pcollaborations\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partners drive ¥112.3bn growth: capital, faster R\u0026amp;D, nationwide reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partners: J-STAR (12% stake; ¥8.5bn equity\/mezzanine since 2022), intl. biotech licensors (cuts R\u0026amp;D ¥5–15bn\/program; speeds launch 12–24 months), major wholesalers (Toho, Alfresa; reach ~20,000 sites; domestic sales ~70% of ¥112.3bn 2024), CMOs (35% volume; ¥2.4bn capex avoided 2024), universities (trial success value +15% vs 2022).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024–25 impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJ-STAR\u003c\/td\u003e\n\u003ctd\u003e¥8.5bn; 12% stake\u003c\/td\u003e\n\u003ctd\u003eCapital stability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech licensors\u003c\/td\u003e\n\u003ctd\u003e¥5–15bn\/prog; -12–24mo\u003c\/td\u003e\n\u003ctd\u003eBiosimilars growth ~25% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e20,000 sites; 70% sales\u003c\/td\u003e\n\u003ctd\u003eNationwide coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003e35% volume; ¥2.4bn saved\u003c\/td\u003e\n\u003ctd\u003eCapex avoidance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUniversities\u003c\/td\u003e\n\u003ctd\u003e+15% trial value\u003c\/td\u003e\n\u003ctd\u003eHigher success\/shift to specialty\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Nichi-Iko Pharmaceutical covering customer segments, channels, value propositions, key activities, resources, partners, cost structure, and revenue streams, reflecting real-world operations and competitive advantages; ideal for presentations, investor discussions, and strategic planning with linked SWOT insights and polished narrative for decision-makers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Nichi-Iko Pharmaceutical’s business model with editable cells to quickly identify product pipelines, distribution channels, and revenue streams—perfect for brainstorming, boardroom presentations, or fast internal alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Quality Generic Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNichi-Iko runs large-scale generic drug manufacturing under strict GMP, producing oral solids, injectables, and specialized formulations for chronic diseases; by late 2025 capacity reached ~1.2 billion units\/year with a plant utilization \u0026gt;90%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRigorous Quality Control and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn response to past regulatory issues, Nichi-Iko Pharmaceutical has made quality assurance a core activity: since 2020 it increased QC staffing by 35% and runs 24\/7 production-line monitoring, tests 100% of incoming raw-material batches and performs monthly internal audits to meet PMDA (Pharmaceuticals and Medical Devices Agency) standards. Maintaining these controls is vital to restore trust with hospitals and regulators and reduce recall risk—recalls fell 78% from 2019–2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA significant share of Nichi-Iko’s operations focuses on biosimilar R\u0026amp;D and clinical trials, requiring biologics expertise and high-capacity labs to replicate reference proteins; by FY2024 the company increased R\u0026amp;D spend to ¥6.8bn (up 18% year-on-year) to support this shift. These investments underpin a 2026 strategy to move into higher-value biologics, targeting biosimilar launches that could raise gross margin by 4–6 percentage points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Inventory Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSupply Chain and Inventory Management coordinates raw-material suppliers, three domestic manufacturing sites, and distributors to keep critical drugs in stock; Nichi-Iko reported 98.7% fill-rate in FY2024 and reduced stockouts by 42% versus FY2020 using integrated ERP and supplier dual-sourcing.\u003c\/p\u003e\n\u003cp\u003eThe company runs AI-driven demand forecasting tied to JPY-denominated safety stock targets (covering ~90 days for essential SKUs) to shield patients from market volatility and Japan’s chronic shortage risks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e98.7% fill-rate FY2024\u003c\/li\u003e\n\u003cli\u003e42% fewer stockouts since FY2020\u003c\/li\u003e\n\u003cli\u003e~90 days safety stock for essential SKUs\u003c\/li\u003e\n\u003cli\u003eThree domestic manufacturing sites\u003c\/li\u003e\n\u003cli\u003eAI forecasting + dual-sourcing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Lifecycle Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNichi-Iko manages over 1,200 active drug registrations and files ~150 PMDA dossiers annually, coordinating approvals for generics while adapting to Japan’s 2024–25 drug price revisions that cut some margins by up to 5%. Lifecycle actions—patent strategies, formulation tweaks, and price renegotiations—lifted core product EBITDA by ~3.5% in FY2024 and smoothed launch timing for 18 new generics in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,200 active registrations\u003c\/li\u003e\n\u003cli\u003e~150 PMDA dossiers\/year\u003c\/li\u003e\n\u003cli\u003eFY2024 EBITDA gain ~3.5%\u003c\/li\u003e\n\u003cli\u003e18 generics launched in 2024\u003c\/li\u003e\n\u003cli\u003ePrice revision impact up to −5% on some drugs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh‑capacity GMP leader: 1.2B units, 98.7% fill‑rate, accelerating biosimilars R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNichi-Iko runs high-volume GMP manufacturing (1.2bn units\/yr, \u0026gt;90% utilization), strict QA (24\/7 monitoring, 100% raw-material testing; recalls −78% 2019–24), growing biosimilars R\u0026amp;D (¥6.8bn FY2024, +18% YoY), strong supply performance (98.7% fill-rate FY2024, 42% fewer stockouts vs FY2020) and regulatory throughput (~1,200 regs, ~150 PMDA dossiers\/yr).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing capacity\u003c\/td\u003e\n\u003ctd\u003e~1.2bn units\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlant utilization\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQC staffing change\u003c\/td\u003e\n\u003ctd\u003e+35% since 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend FY2024\u003c\/td\u003e\n\u003ctd\u003e¥6.8bn (+18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill-rate FY2024\u003c\/td\u003e\n\u003ctd\u003e98.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive registrations\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Nichi-Iko Pharmaceutical Business Model Canvas—not a mockup—and reflects the exact document you’ll receive after purchase. Upon completing your order, you’ll get this same ready-to-use file, fully formatted and editable for presentation or analysis. No placeholders, no extras—what you see is the deliverable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749756350841,"sku":"nichiiko-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/nichiiko-business-model-canvas.png?v=1772218005","url":"https:\/\/growthsharematrix.com\/products\/nichiiko-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}